https://www.selleckchem.com/pr....oducts/Bleomycin-sul
Introduction Acute kidney injury (AKI) is a complex and common condition associated with increased morbidity, mortality, and costs. Evidence from cost-effectiveness analysis (CEA) have targeted various aspects of AKI including detection with biomarkers, treatment with renal replacement therapy, and prevention when using contrast media. However, there has not been a systematic review of these studies across the entirety of AKI.Areas covered PubMed, Embase, and Cochrane library were used to identify CEA studies that involved AKI
Synes godt om
Kommentar
Del
